{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:23:23Z","timestamp":1787415803626,"version":"build-2736575974"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital\/real-world evidence, genetics, artificial intelligence (AI), and implementation\/global-access themes that are endorsed by international societies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Therapeutic gains include rapid-acting drugs for treatment-resistant depression (intranasal esketamine); psychedelic-assisted therapy for posttraumatic stress disorder and depression; neuroactive steroid \u03b3-aminobutyric acid-A receptor positive allosteric modulators (brexanolone, zuranolone) for postpartum depression; non-dopaminergic muscarinic agonists (xanomeline\u2013trospium) for schizophrenia; orexin receptor antagonists for insomnia; and anti-amyloid monoclonal antibodies (lecanemab, donanemab) for early Alzheimer\u2019s disease. Persistent barriers include high mid-\/late-stage attrition that is driven by placebo effects, subjective endpoints, and preclinical-to-clinical gaps; regulatory and economic headwinds; and limited generalizability from tightly run trials. Emerging enablers include adaptive\/platform designs, digital health technologies, patient-reported outcomes, and clinical outcome assessments, real-world evidence (RWE), AI\/machine learning (ML), genetics for target de-risking and biomarker-guided stratification, and publicly accessible large CNS relevant biological datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To convert momentum into durable progress, we recommend: (1) deeper academia\u2013industry\/stakeholder collaboration and sustained funding for high-risk\/high-reward science from industry, governments, and non-for profit foundations; (2) modernized regulation (flexible evidentiary paths, novel endpoints, and clear guidance on adaptive\/platform trials); (3) data-driven development integrating RWE, AI\/ML, and precision medicine; (4) the adoption of Neuroscience-based Nomenclature; and (5) a global-access mandate with essential-medicine inclusion, equitable pricing\/licensing, capacity building, tele-enabled mental health, and geographically diverse research. Aligning scientific innovation with implementation and equity can accelerate translation and ensure new treatments benefit patients worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag023","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:29:10Z","timestamp":1777980550000},"source":"Crossref","is-referenced-by-count":0,"title":["Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-7036","authenticated-orcid":false,"given":"Hiroyuki","family":"Uchida","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine (International College of Neuropsychopharmacology, CINP) , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-9825","authenticated-orcid":false,"given":"Gabriella","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, McGill University (CINP) , Montreal ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-9104","authenticated-orcid":false,"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, and National Post-Trauma Center, Sheba Medical Center (CINP) , Ramat Gan ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Imperial College London (CINP) , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Vienna (CINP) , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-9834","authenticated-orcid":false,"given":"Ming-Chyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Taipei City Psychiatric Center, Taipei City Hospital and Department of Psychiatry, Taipei Medical University (CINP) , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Sundram","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Monash University (Asian College of Neuropsychopharmacology, AsCNP) , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukoye","family":"Atwoli","sequence":"additional","affiliation":[{"name":"Medical College East Africa, Aga Khan University (African College of Neuropsychopharmacology, AfCNP) , Nairobi ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Vukovic","sequence":"additional","affiliation":[{"name":"Queensland Brain Institute, The University of Queensland (International Brain Research Organization, IBRO) , Brisbane ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"National Center of Neurology and Psychiatry (NCNP), CINP , Tokyo ,","place":["Japan"]},{"name":"Tokyo Metropolitan Institute of Medical Science (CINP) , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026082211413388800_ref1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"2026082211413388800_ref2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"2026082211413388800_ref3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"2026082211413388800_ref4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry."},{"key":"2026082211413388800_ref5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"2026082211413388800_ref6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082211413388800_ref7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"2026082211413388800_ref8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1126\/science.ads4470","article-title":"What's next for psychedelics after MDMA rejection?","volume":"385","author":"Kupferschmidt","year":"2024","journal-title":"Science."},{"key":"2026082211413388800_ref9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082211413388800_ref10","author":"ClinicalTrials.gov"},{"key":"2026082211413388800_ref11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"key":"2026082211413388800_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13481","article-title":"Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial","volume":"334","author":"Robison","year":"2025","journal-title":"JAMA."},{"key":"2026082211413388800_ref13","author":"ClinicalTrials.gov"},{"key":"2026082211413388800_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03169-9","article-title":"Above the threshold, beyond the trip: the role of the 5-HT(2A) receptor in psychedelic-induced neuroplasticity and antidepressant effects","volume":"30","author":"Drewko","journal-title":"Mol Psychiatry"},{"key":"2026082211413388800_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2025.06.012","article-title":"The polypharmacology of psychedelics reveals multiple targets for potential therapeutics","volume":"113","author":"Jain","journal-title":"Neuron."},{"key":"2026082211413388800_ref16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","article-title":"GABA(A)R plasticity during pregnancy: relevance to postpartum depression","volume":"59","author":"Maguire","year":"2008","journal-title":"Neuron."},{"key":"2026082211413388800_ref17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/s0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet."},{"key":"2026082211413388800_ref18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am J Psychiatry"},{"key":"2026082211413388800_ref19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"2026082211413388800_ref20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"2026082211413388800_ref21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082211413388800_ref22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet."},{"key":"2026082211413388800_ref23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082211413388800_ref24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2026082211413388800_ref25","doi-asserted-by":"publisher","first-page":"110275","DOI":"10.1016\/j.neuropharm.2024.110275","article-title":"Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately\/poorly responding patients with chronic schizophrenia: results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial","volume":"266","author":"Anand","year":"2025","journal-title":"Neuropharmacology."},{"key":"2026082211413388800_ref26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026082211413388800_ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0092-8674(02)09256-5","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell."},{"key":"2026082211413388800_ref28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell."},{"key":"2026082211413388800_ref29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0092-8674(00)81973-x","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell."},{"key":"2026082211413388800_ref30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026082211413388800_ref31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2026082211413388800_ref32","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep."},{"key":"2026082211413388800_ref33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026082211413388800_ref34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082211413388800_ref35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1212\/WNL.0000000000207438","article-title":"Implications of the approval of lecanemab for Alzheimer disease patient care: incremental step or paradigm shift?","volume":"101","author":"Knopman","year":"2023","journal-title":"Neurology."},{"key":"2026082211413388800_ref36","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer's disease drug development pipeline","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"key":"2026082211413388800_ref37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"2026082211413388800_ref38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science."},{"key":"2026082211413388800_ref39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature."},{"key":"2026082211413388800_ref40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2026082211413388800_ref41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife."},{"key":"2026082211413388800_ref42","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"2026082211413388800_ref43","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/mp.2008.28","article-title":"Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia","volume":"14","author":"Scarr","year":"2009","journal-title":"Mol Psychiatry"},{"key":"2026082211413388800_ref44","doi-asserted-by":"publisher","first-page":"101982","DOI":"10.1016\/j.xcrm.2025.101982","article-title":"The gut microbiota-immune-brain axis: therapeutic implications","volume":"6","author":"O'Riordan","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026082211413388800_ref45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"2026082211413388800_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.repolx.2020.100008","article-title":"Socializing the risks and rewards of public investments: economic, policy, and legal issues","volume":"49","author":"Laplane","year":"2020","journal-title":"Res Policy"},{"key":"2026082211413388800_ref47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/ACM.0b013e3181ccb74d","article-title":"Linking scientific discovery and better health for the nation: the first three years of the NIH\u2019s Clinical and Translational Science Awards","volume":"85","author":"Califf","year":"2010","journal-title":"Acad Med"},{"key":"2026082211413388800_ref48","author":"European Commission"},{"key":"2026082211413388800_ref49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics."},{"key":"2026082211413388800_ref50","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2026082211413388800_ref51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"key":"2026082211413388800_ref52","author":"U. S. Food and Drug Administration"},{"key":"2026082211413388800_ref53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide\u2014identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun."},{"key":"2026082211413388800_ref54","author":"U. S. Food and Drug Administration"},{"key":"2026082211413388800_ref55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrd4578","article-title":"Mitigating risk in academic preclinical drug discovery","volume":"14","author":"Dahlin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2026082211413388800_ref56","author":"U. S. Food and Drug Administration"},{"key":"2026082211413388800_ref57","doi-asserted-by":"publisher","first-page":"155cm11","DOI":"10.1126\/scitranslmed.3003142","article-title":"Revolution stalled","volume":"4","author":"Hyman","year":"2012","journal-title":"Sci Transl Med"},{"key":"2026082211413388800_ref58"},{"key":"2026082211413388800_ref59","author":"National Institutes of Health"},{"key":"2026082211413388800_ref60","author":"Accelerating Clinical Trials"},{"key":"2026082211413388800_ref61","author":"Japan Agency for Medical Research and Development"},{"key":"2026082211413388800_ref62","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/jmg.2008.063701","article-title":"A pilot open label, single dose trial of fenobam in adults with fragile X syndrome","volume":"46","author":"Berry-Kravis","year":"2009","journal-title":"J Med Genet"},{"key":"2026082211413388800_ref63","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/embor.2009.193","article-title":"The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery","volume":"10","author":"Weigelt","year":"2009","journal-title":"EMBO Rep"},{"key":"2026082211413388800_ref64","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fmed.2019.00275","article-title":"The innovative medicines initiative -10 years of public-private collaboration","volume":"6","author":"Laverty","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2026082211413388800_ref65","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41386-018-0030-z","article-title":"Relapse prediction in schizophrenia through digital phenotyping: a pilot study","volume":"43","author":"Barnett","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"2026082211413388800_ref66","author":"European Medicines Agency"},{"key":"2026082211413388800_ref67","author":"European Medicines Agency"},{"key":"2026082211413388800_ref68","author":"U.S. Food and Drug Administration"},{"key":"2026082211413388800_ref69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2026082211413388800_ref70","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1017\/S146114571100040X","article-title":"Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study","volume":"14","author":"Vieta","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026082211413388800_ref71","first-page":"19","article-title":"Current and emerging technologies to address the placebo response challenge in CNS clinical trials: promise, pitfalls, and pathways forward","volume":"21","author":"Horan","year":"2024","journal-title":"Innov Clin Neurosci"},{"key":"2026082211413388800_ref72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/cpt.2272","article-title":"Understanding use of real-world data and real-world evidence to support regulatory decisions on medical product effectiveness","volume":"111","author":"Mahendraratnam","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026082211413388800_ref73","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1002\/alz.13785","article-title":"Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset","volume":"20","author":"Galvin","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026082211413388800_ref74","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091277","article-title":"The effects of CYP2C19 genotype on proxies of SSRI antidepressant response in the UK Biobank","volume":"16","author":"Wong","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026082211413388800_ref75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature."},{"key":"2026082211413388800_ref76","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature."},{"key":"2026082211413388800_ref77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41431-023-01471-0","article-title":"Specific measures for data-intensive health research without consent: a systematic review of soft law instruments and academic literature","volume":"32","author":"Smit","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"2026082211413388800_ref78","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11019-022-10134-8","article-title":"Towards trust-based governance of health data research","volume":"26","author":"Bak","year":"2023","journal-title":"Med Health Care Philos"},{"key":"2026082211413388800_ref79","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/wps.20883","article-title":"The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality","volume":"20","author":"Torous","year":"2021","journal-title":"World Psychiatry"},{"key":"2026082211413388800_ref80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41398-025-03497-y","article-title":"Recent developments in omics studies and artificial intelligence in depression and suicide","volume":"15","author":"Wang","year":"2025","journal-title":"Transl Psychiatry"},{"key":"2026082211413388800_ref81","doi-asserted-by":"publisher","DOI":"10.1055\/a-2810-8972","article-title":"Artificial intelligence in drug discovery and development: raising quality per decision","volume":"59","author":"Furukawa","journal-title":"Pharmacopsychiatry."},{"key":"2026082211413388800_ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104009","article-title":"How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons","volume":"29","author":"Kp Jayatunga","year":"2024","journal-title":"Drug Discov Today"},{"key":"2026082211413388800_ref83","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cpt.3542","article-title":"Progress, pitfalls, and impact of AI-driven clinical trials","volume":"117","author":"Wilczok","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026082211413388800_ref84","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1017\/s0033291722002124","article-title":"Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report","volume":"53","author":"Sajjadian","year":"2023","journal-title":"Psychol Med"},{"key":"2026082211413388800_ref85","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science."},{"key":"2026082211413388800_ref86","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41586-025-09820-3","article-title":"Mapping the genetic landscape across 14 psychiatric disorders","volume":"649","author":"Grotzinger","year":"2026","journal-title":"Nature."},{"key":"2026082211413388800_ref87","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature."},{"key":"2026082211413388800_ref88","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041209","article-title":"Genome-environment interactions and psychiatric disorders","volume":"11","author":"Peedicayil","year":"2023","journal-title":"Biomedicines"},{"key":"2026082211413388800_ref89","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41398-022-02076-9","article-title":"Cell-type-specific epigenetic effects of early life stress on the brain","volume":"12","author":"Rahman","year":"2022","journal-title":"Transl Psychiatry"},{"key":"2026082211413388800_ref90","author":"European Medicines Agency"},{"key":"2026082211413388800_ref91","author":"Psychiatric Genomics Consortium"},{"key":"2026082211413388800_ref92","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026082211413388800_ref93","author":"Neuroscience-based Nomenclature"},{"key":"2026082211413388800_ref94","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","article-title":"Undertreatment of people with major depressive disorder in 21 countries","volume":"210","author":"Thornicroft","year":"2017","journal-title":"Br J Psychiatry"},{"key":"2026082211413388800_ref95","author":"World Health Organization"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag023\/68244801\/pyag023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/8\/pyag023\/68244801\/pyag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/8\/pyag023\/68244801\/pyag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:41:37Z","timestamp":1787413297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag023\/8672011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag023","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"pyag023"}}